NYSE: LLY
Eli Lilly and Company (LLY) is a global pharmaceutical leader dedicated to discovering, developing, and delivering innovative medicines that improve lives. Headquartered in Indianapolis, Indiana, Lilly focuses on cutting-edge research in oncology, diabetes, neuroscience, and immunology, with a robust pipeline of breakthrough therapies. The company is at the forefront of the biopharmaceutical industry, leveraging advanced technology, strategic acquisitions, and AI-driven drug discovery to accelerate innovation. With a commitment to addressing some of the world's most pressing health challenges, Lilly continues to expand access to life-changing treatments while driving sustainable growth. Through its investments in next-generation biologics, personalized medicine, and global partnerships, Eli Lilly remains a key player in shaping the future of healthcare.
“Investing in Eli Lilly and Company grants access to a leader in the healthcare sector where GLP-1 agonists and biopharmaceuticals are advancing and expanding rapidly throughout the medical world. Investors can reap the benefits through stable and prolonged financial growth with long-term returns paired with low-risk and dividend payouts. New AI technologies and extensive research will result in higher spending to foster groundbreaking medical innovation, improve global health, and contribute to better patient outcomes.”
Donald Downer II, Director
Overview
A “new” drug known to some as the “Billion Dollar shot” has taken the pharmaceutical industry's Healthcare sector by storm. Many companies have made strides in the area of diabetic research by using name brands like Monjauro, Ozempic, Wegovy, and Rybelsus. The active ingredients in those diabetic drugs are typically semaglutide and tirzepatide which are GLP-1 agonists that reduce the release of glucagon and the uptake of glucose. Once the public started to realize that these injections and/or tablets were more than just GLP-1 agonists and also contained a very impactful side effect beyond their initial purpose, which is weight loss, the stocks and industry began to shift toward this type of research and now people who are not diabetic have began to use those drugs due to their safety and the fact that they have been FDA approved.
Eli Lilly and Company makes Monjuaro and is a leader in the global pharmaceutical industry, specializing in drug development in diabetes, oncology, immunology, and neuroscience. It was founded in 1876, and is headquartered in Indianapolis, Indiana. It has a strong reputation for a research-driven approach focusing on biopharmaceuticals and groundbreaking treatments that address many modern medical challenges.
Superior Return on Investment (ROI):
Eli Lilly has demonstrated superior financial performance with a five-year total return of close to 350%, which showcases a strong return on investment. The ROI is at 24.38%, representing a significant 47.98% increase from December 31, 2023, to December 31, 2024. This growth reflects the company’s ability to generate consistent returns for investors and highlights its ongoing commitment to profitability with a projected annual revenue growth rate of about 15% CAGR per year for the past 5 years. The company is positioned for continued success, especially when the earnings per share (EPS) have been strong and have been reaching $11.76 annually. In Q4 of 2024, the EPS was $5.32 and the price-to-earnings (P/E) ratio of 67.80 as of March 2025 suggests that it has high expectations for future earnings. This expectation may indicate the potential for a price correction, however, due to the price-to-book (P/B) ratio of 50.8 being fairly high for this type of company, it means that investors are still confident in the company’s future and are willing to pay a premium for its shares. The return on equity (ROE) of 77.8% far exceeds the industry average and demonstrates the company’s ability to make impressive returns to the shareholders.
Financial Stability & Strength:
The company’s financial position is robust, with a market capitalization of around $770 billion. Despite a relatively high debt-to-equity (D/E) ratio of 2.37 as of December 2024, the company’s strong cash flow effectively manages its debt. The free cash flow (FCF) has surged to $3.76 billion, representing a dramatic 374% increase from 2022, signaling an incredible comeback from the previous low of $.793 billion. This strong cash flow bolsters the company's capacity to make growth investments and preserve financial flexibility. Furthermore, the company's efficiency in turning a profit is demonstrated by its operating margin of 30.26%, which is much higher than the industry average. The success of its diabetes and weight-loss medications has contributed to its remarkable revenue growth, which has increased by 58.03% in just two years. The company's financial strength was further reinforced when it reported a 35% year-over-year (YoY) revenue growth, driven primarily by sales of GLP-1 medications
Market Leadership & Product Performance:
The company maintains a dominant position in the market and has been performing exceptionally well, with Mounjaro sales reaching $3.53 billion in Q4 2024, marking a 60% increase in YoY. Zepbound, similar to Mounjaro, also contributed significantly with $1.9 billion in sales during the same period. The company reported a Q4 2024 profit of $4.41 billion, more than doubling YoY, and adjusted EPS for the same time frame came in at $5.32, surpassing the previous expectations. Lastly, the company’s beta of 0.46x indicates that the stock of Eli Lilly is low risk, which is perfect for investors seeking stability, especially in the healthcare sector which is already one of the most stable.
Competitive Edge Over Industry Peers:
With an estimated 45% market share in the GLP-1 segment, Eli Lilly has a significant competitive advantage over Viking Therapeutics but lags behind Novo Nordisk. The company's main advantages include the superior efficacy of its top drug, Mounjaro, compared to rivals like Ozempic and its strong market positioning in diabetes and exceptional treatments. The business also has a strong and growing research and development (R&D) pipeline, focusing on neuroscience, oncology, and metabolic disorders.
Eli Lilly has also made calculated investments in next-generation biologics and AI-driven drug discovery to ensure ongoing innovation and expansion.
Dividends & Yield:
Eli Lilly offers a steady dividend yield of about 0.75% with an annual dividend payout of around $5.20 per share. The company has maintained a consistent dividend growth trajectory, with a 5-year dividend growth rate of 15% CAGR. In December of 2024, Eli Lilly reported a 15.4% increase in its dividend, reflecting the company’s strong financial health and commitment to returns to its shareholders. The payout ratio is 43%, which provides plenty of room for reinvestment and future dividend hikes. Eli Lilly continues to demonstrate its long-term stability and commitment to shareholders with over 35 years of consecutive dividend payments and 11 years of uninterrupted dividend growth.
Market Trends & Future Outlooks:
Eli Lilly should maintain its market dominance due to its strong position in the GLP-1 therapies space, where Mounjaro and Zepbound are at the forefront of obesity and diabetes treatments. LLY will continue to thrive and rise in markets that allow for large healthcare spending, like the continued growth of global healthcare investments. Eli Lilly’s strong financial foundation, characterized by stable cash flow and a high reinvestment in R&D, supports its ability to maintain a competitive edge in the industry if it keeps outperforming the market. The company's trajectory of consistent profitability is expected to be reinforced by projected 2025 revenue, which is expected to range between $58 billion and $61 billion, with an EPS of $22.50 to $24.00. Eli Lilly's portfolio and treatment innovation would be further enhanced by strategic acquisitions, such as the possible $2.5 billion purchase of Scorpion Therapeutics. Further solidifying its market leadership and guaranteeing sustained long-term growth is the company's global expansion into emerging markets, such as China, India, Brazil, and Mexico, by 2025.
Final Takeaways
Underpinned by remarkable EPS and a high ROE of 77.8%, Eli Lilly exhibits strong financial performance with a five-year total return of nearly 350% and a 24.38% ROI. Robust free cash flow, a 30.26% operating margin, and notable revenue growth—fueled by the company's popular Mounjaro and Zepbound medications—all contribute to its financial stability. Eli Lilly's competitive advantage is derived from its superior product efficacy, growing R&D pipeline, and calculated investments in AI-driven drug discovery and next-generation biologics. With steady dividend growth, a 15% compound annual growth rate, and estimated revenue of $58–$61 billion in 2025, Eli Lilly is well-positioned to maintain its market leadership and grow internationally, guaranteeing investors long-term value.
Disclaimer
This article is for informational and educational purposes only and should not be considered financial, investment, or professional advice. The content is based on publicly available sources and research, including but not limited to:
Bloomberg (March 10, 2025) – Eli Lilly's Market Expansion and GLP-1 Drug Dominance
U.S. Food and Drug Administration (FDA) – Regulatory Approvals and Clinical Trials for GLP-1 Medications
Pharmaceutical Research and Manufacturers of America (PhRMA) – Trends in Biopharmaceutical R&D Investment
Eli Lilly & Company – Investor Relations Report (Q4 2024) – Financial Performance, Earnings Growth, and Market Position
MarketWatch – Historical Stock Performance of Eli Lilly (LLY)
Global Diabetes and Obesity Treatment Trends – Data from World Health Organization (WHO)
Mergers & Acquisitions Report – Analysis of Eli Lilly’s Strategic Investments in 2024
While every effort has been made to ensure the accuracy and reliability of the information presented, Pathway Investments does not guarantee the completeness or timeliness of the data. The article includes research assisted by artificial intelligence (AI) tools, used solely for synthesizing publicly available information and generating insights.
Readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Pathway Investments does not endorse or recommend any specific securities, financial instruments, or investment strategies discussed in this article.
Pathway Investments and its affiliates assume no liability for any financial losses or decisions made based on the content of this publication.